STOCK TITAN

Pfizer Inc. - PFE STOCK NEWS

Welcome to our dedicated news page for Pfizer (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pfizer's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pfizer's position in the market.

Rhea-AI Summary
Pfizer Inc. reported a significant decline in revenues for the fourth quarter and full-year 2023, with a 41% operational decrease in year-over-year revenues. The decline was driven by a decrease in Comirnaty and Paxlovid revenues, offset by growth in new product and indication launches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
earnings
-
Rhea-AI Summary
Pfizer and Astellas announced that the European Medicines Agency has validated for review a Type II variation application for PADCEV with KEYTRUDA as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer. The combination significantly extended overall and progression-free survival, potentially offering an alternative to platinum-containing chemotherapy. The application is based on results from the Phase 3 EV-302 clinical trial, demonstrating statistically significant and clinically meaningful results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) has received an unsolicited mini-tender offer from TRC Capital Investment Corporation to purchase up to 4 million shares of Pfizer common stock at a price of $27.35 per share in cash. The offer price is approximately 4.4 percent lower than the closing share price on December 27, 2023. Pfizer does not endorse the offer and recommends that stockholders do not tender their shares due to the offer being below the current market price and subject to numerous conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
Rhea-AI Summary
Genmab A/S (GMAB) and Pfizer, Inc. (PFE) announced that the FDA has accepted the sBLA for TIVDAK, with a PDUFA action date of May 9, 2024. This is based on positive results from the global phase 3 innovaTV 301 trial, demonstrating an overall survival benefit of tisotumab vedotin-tftv over chemotherapy for the treatment of patients with recurrent or metastatic cervical cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
none
-
Rhea-AI Summary
Genmab A/S (GMAB) and Pfizer, Inc. (PFE) announced that the FDA has accepted the sBLA for TIVDAK, with a PDUFA action date of May 9, 2024. This is based on positive results from the global phase 3 innovaTV 301 trial, demonstrating an overall survival benefit of tisotumab vedotin-tftv over chemotherapy for the treatment of patients with recurrent or metastatic cervical cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
-
Rhea-AI Summary
Pfizer Inc. (PFE) and Genmab A/S (GMAB) announced the FDA's acceptance of the supplemental Biologics License Application (sBLA) seeking to convert the accelerated approval of TIVDAK to full approval for the treatment of patients with recurrent or metastatic cervical cancer with disease progression. The Phase 3 innovaTV 301 trial demonstrated a favorable benefit/risk profile, including improvement in overall survival, progression-free survival, and confirmed objective response rate in patients with previously treated recurrent or metastatic cervical cancer compared to chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
none
Rhea-AI Summary
Pfizer Inc. (PFE) and Genmab A/S (GMAB) announced the FDA's acceptance of the supplemental Biologics License Application (sBLA) seeking to convert the accelerated approval of TIVDAK to full approval for the treatment of patients with recurrent or metastatic cervical cancer with disease progression. The Phase 3 innovaTV 301 trial demonstrated a favorable benefit/risk profile, including improvement in overall survival, progression-free survival, and confirmed objective response rate in patients with previously treated recurrent or metastatic cervical cancer compared to chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
-
Rhea-AI Summary
Pfizer Inc. (PFE) announced that the European Commission has approved TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in the European Union. The approval was based on data from the Phase 3 TALAPRO-2 trial, showing a 37% reduction in the risk of disease progression or death with TALZENNA plus XTANDI compared to placebo plus XTANDI, meeting the primary endpoint of improving radiographic progression-free survival. The safety profile of TALZENNA plus XTANDI was consistent with the known safety profile of each medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
-
Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 3:00 p.m. PST. The webcast will be available on www.pfizer.com/investors, and the transcript and webcast replay will be accessible for at least 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.27%
Tags
conferences
Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 30, 2024. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2023 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
conferences
Pfizer Inc.

NYSE:PFE

PFE Rankings

PFE Stock Data

157.14B
5.64B
0.05%
69.96%
1.27%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Palo Alto

About PFE

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.